Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345341 | 0.90 | CHRM4 (0.42) | CHRM4MEN1KMT2ACKS1BSKP1 | |
| SCHEMBL345122 | 0.90 | CHRM4 (0.43) | CHRM4TDP1MEN1KMT2ACKS1B | |
| SCHEMBL345619 | 0.86 | TDP1 (0.38) | CHRM4TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL345663 | 0.83 | CHRM4 (0.42) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL345419 | 0.81 | CHRM4 (0.44) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL345683 | 0.80 | CHRM4 (0.42) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL344764 | 0.80 | CHRM4 (0.43) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL2406863 | 0.79 | CHRM4 (0.45) | CHRM4TDP1L3MBTL1CKS1BSKP1 | |
| SCHEMBL345267 | 0.79 | NPC1 (0.43) | CHRM4MEN1KMT2ANPC1POLB | |
| SCHEMBL345157 | 0.79 | CHRM4 (0.43) | CHRM4TDP1L3MBTL1CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CHRM4 1210/4885TDP1 2834/4885L3MBTL1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.